Max joined Frazier Healthcare Partners in 2019 and focuses on identifying and evaluating new investment opportunities in the life sciences sector.
Prior to joining Frazier, Max founded and managed a small investment fund whose strategies included mispricing identification in public biotech equities as well as the development of mechanical systems for use in other asset classes, with an emphasis on risk management and risk-adjusted returns. Previously, Max was a senior business analyst at Zymergen where he worked on internal strategy initiatives and developed a comprehensive dynamic operating model for the company’s proprietary high-throughput genetic engineering methodology. Max began his career in New York as an investment banking analyst in the healthcare mergers & acquisitions group at Evercore Partners, focusing on biotech and medtech companies.
Max received his M.D. from the Weill Cornell Medical College of Cornell University, where he was awarded the Siegel Family Student Prize, and his B.A. in physics and biochemistry from Bowdoin College.